Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
IMAX heads into its October 23 earnings date with short sellers rebuilding positions, the stock down 10% on the week, and an activist on the share register, all while the analyst community stays firmly bullish.
The most striking move this week is in short interest, which has climbed 5.6% over the past seven days to 12.4% of the free float. That is a meaningful level for a single-name entertainment stock, and the direction of travel matters as much as the level. Short sellers added roughly 460,000 shares net over the week. The borrow market remains relaxed, with availability at 256%, meaning there are more than two and a half shares available for every share currently lent out, well above its 52-week low of 90%. Cost to borrow is just 0.51%, barely above risk-free. That combination tells a specific story: shorts are adding conviction, but they are doing so cheaply and without any squeeze pressure. The ORTEX short score has ticked up to 65.3, near its recent high, confirming the directional lean.
Options positioning cuts against that bearish build. The put/call ratio has dropped to 1.49, below its 20-day average of 2.31, a shift that signals options traders are actually less defensive than they have been for most of September. The 20-day mean was being dragged higher by a stretch of heavy put activity through early September, when the PCR ran above 3.5. That overhang has unwound sharply. The current reading is 0.7 standard deviations below the recent average, meaning the options market is not hedging into earnings with the same intensity as last month. Two signals, two different reads: the short book is growing, but derivatives traders have eased off the protection trade.
The Street is broadly constructive. Morgan Stanley initiated coverage with an Overweight rating and a $63 target on September 24, and StoneX raised its target to $65 this week while keeping a Buy. Goldman Sachs is the outlier, maintaining Neutral with a $50 target raised from $42 in early September, a level that now sits almost exactly at the current price of $50.58. The mean analyst target across the coverage universe is $56.33, implying around 11% upside from current levels. The bull case rests on IMAX's screen economics: generating $485 million in gross box office from The Odyssey on less than 1% of global screens, with 421 systems in backlog and a content slate expanding to over 120 titles this year. The bear case is China concentration and the inherent lumpiness of blockbuster dependence, with Dune: Part Three the next major test in Q4. Factor scores reinforce the bullish tilt: the 12-month forward EPS estimate momentum ranks in the 86th percentile of the ORTEX universe, and analyst recommendation divergence ranks in the 95th percentile, meaning IMAX is more unanimously liked by analysts than almost any stock covered.
The ownership picture carries one genuinely newsworthy element. Kevin Douglas holds a Schedule 13D activist position, filing twice this year and most recently in March. His latest disclosed stake was 15.5% of shares, trimmed from 16.5%, representing roughly 8.4 million shares. A 13D filer signals an intent to engage actively with management, not passive ownership. That is worth flagging, though the standard caveat applies: 13D and 13G stakes are event-driven disclosures around the 5% threshold, and positions may have moved since the last filing without a new disclosure requirement. The broader institutional base has been adding exposure. BlackRock increased its position by 290,000 shares to a 5.3% stake through September 30. Westfield Capital added 315,000 shares through July. Congress Asset Management lifted its stake by over a million shares. Against that, insider activity ran firmly in the other direction. The 90-day net insider position shows 552,757 shares sold for a net value of roughly $29 million. CEO Richard Gelfond exercised and sold options under a pre-arranged 10b5-1 plan in August, accounting for the bulk of that figure. The CLO and the CFO made smaller discretionary sales in late August and September with no 10b5-1 flag, which is a detail worth noting even if the amounts are modest.
Earnings history offers useful framing for the October 23 release. The last print, in late July, produced a 10.4% one-day move and an 21.1% five-day move to the upside. The print before that delivered 2.6% on day one and 8.8% over five days. Both were positive. The stock has pulled back 10% this week and 2% over the past month from what was a strong YTD run. Whether the rebuilding short position reflects a genuine view on the Q3 print or is simply profit-taking discipline ahead of a historically volatile event is what the next 16 days should clarify.
See the live data behind this article on ORTEX.
Open IMAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
